植耀輝:美股偏軟納指連跌三周 恆指恐續尋底
耀才證券研究部總監植耀輝稱,美股上周五(18日)個別發展,收市計三大指數變化不大。不過全周計,三大指數均累跌超過2%,當中道指累跌2.2%,標普500指數亦跌2.1%。納指跌幅則達到2.6%,連續第三個星期下跌。
A股走勢亦欠佳,上周五滬深兩市均以全日最低位收市,全周計則上綜指下跌1.8%,深成指跌幅則達到3.2%。
港股表現亦強差人意,恆指上周五失守萬八點關口,最低見17,900點,最終收報17,950點,下跌375點或2.1%,科指則跌3.6%,收報4,007點,成交金額則達到1,063億元。全周計,恆指急挫5.9%,科指跌幅更達到6.2%,而8月至今恆指已累跌10.6%,科指則跌近12%。恆指成份股上周全線下跌,跌幅最大為碧桂園(02007.HK),跌幅達到22.5%,另醫療平台股亦大跌,京東健康(06618.HK)及阿里健康(00241.HK)一周累跌19%及18%。
至於本周焦點,外圍方面有Jackson Hole銀行家年會,投資者關注聯儲局主席鮑威爾之講話;至於本地方面則繼續有藍籌股公布業績,當中便包括舜宇(02382.HK)、美團-W(03690.HK)及中石化(00386.HK)等。當然A股表現、人民幣匯價走勢以至內股消息亦需關注。在眾多不明朗因素困擾下,預期恆指或持續尋底,並可能進一步考驗17,600點水平。
(筆者為證監會持牌人,並未持有相關股份)
********
金龍指數偏軟 業績期港股續反覆
耀才研究部稱,美股上周五(18日)個別發展,道指微升25點,標普500指數及納指則下跌,惟跌幅不大。至於反映中概股表現之金龍指數則大跌3.48%。
港股上周五再度急跌,跌幅更一度達到426點,萬八點亦告失守,最終恆指大跌375點或2.1%,連跌六個交易日,成份股中以醫療平台股表現最差,京東健康(06618.HK)及阿里健康(00241.HK)大跌13%及10.3%,事實上上周五只得3隻成份股錄得升幅。全周計則恆指大跌1,124點或5.9%。科指跌幅亦達到6.2%。另外,恆指服務公司在季檢後宣布,恆指成份股剔除碧桂園(02007.HK),加入國藥控股(01099.HK)。本周為業績發佈高峰期,多隻藍籌續公布業績,另投資者亦繼續關注與內房相關之消息。外圍方面,本周Jackson Hole銀行家年會,投資者亦觀望聯儲局主席鮑威爾之講話。預期在未有更多利好消息前,恆指將續維持尋底格局。
技術走勢方面,恆指「六連跌」之餘,亦正式失守6月至今形成之「雙頂」頸線(約18,300點),走勢亦進一步轉差,若以雙頂頂部約20,300點計算,量度跌幅可達到2,000點。由於恆指已失守萬八關口,下一個支持位亦已順延至去年12月初,亦即17,600點水平。
(筆者為證監會持牌人)~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.